WHO Report Shows Increase in HIV Drug Resistance to Dolutegravir

  10 March 2024

The World Health Organization’s HIV Drug Resistance Report reveals growing drug resistance in populations receiving dolutegravir-containing antiretroviral therapy (ART). However, levels of HIVDR to DTG are exceeding clinical trials. The report recommends dolutegravir as the preferred treatment due to its effectiveness, ease of use, and genetic barrier to resistance. Resistance to dolutegravir ranges from 3.9% to 8.6%, reaching 19.6% among those with high viral loads.

 

Author(s): Pharmaceutical Manufacturer
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed